<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: The International <z:mp ids='MP_0002055'>Diabetes</z:mp> Federation (IDF) has recently established a worldwide consensus definition of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>No prospective data are available on the cardiovascular risk associated with this new <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> definition </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: In a prospective study of 750 coronary patients, we recorded vascular events over 4 years </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: From our patients, 37.3% (n = 280) had the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> according to the Adult Treatment Panel III (ATPIII) definition and 45.5% (n = 341) according to the IDF definition </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> as defined by the ATPIII criteria significantly predicted vascular events (adjusted hazard ratio 1.745 [95% CI 1.255-2.427]; P = 0.001), but the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> as defined by IDF criteria did not (1.189 [0.859-1.646]; P = 0.297) </plain></SENT>
<SENT sid="5" pm="."><plain>Accordingly, event-free survival was significantly lower among patients who fulfilled the ATPIII but not the IDF criteria than among those who met the IDF but not the ATPIII criteria (P = 0.012) </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> as defined by ATPIII criteria remained significantly predictive of vascular events after adjustment for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> but not after additional adjustment for the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> components high <z:chebi fb="4" ids="17855">triglycerides</z:chebi> and <z:hpo ids='HP_0003233'>low HDL cholesterol</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>These <z:chebi fb="23" ids="18059">lipid</z:chebi> traits in turn proved significantly predictive of vascular events even after adjustment for the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: The ATPIII definition of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> confers a significantly higher risk of vascular events than the IDF definition </plain></SENT>
<SENT sid="9" pm="."><plain>However, among angiographied coronary patients, even the ATPIII definition of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> does not provide prognostic information beyond its dyslipidemic features </plain></SENT>
</text></document>